Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include Muscle atrophy, Atrophy, Medicine, Skeletal muscle, Oxidative stress, and Inflammation.
Stem cell therapy: A promising therapeutic approach for skeletal muscle atrophy
Hypoxic-Ischemic Encephalopathy: Pathogenesis and Promising Therapies
Achyranthes bidentata polysaccharide ameliorates type 2 diabetes mellitus by gut microbiota-derived short-chain fatty acids-induced activation of the GLP-1/GLP-1R/cAMP/PKA/CREB/INS pathway
Celecoxib attenuates hindlimb unloading-induced muscle atrophy via suppressing inflammation, oxidative stress and ER stress by inhibiting STAT3
Astragaloside IV Improves Muscle Atrophy by Modulating the Activity of UPS and ALP via Suppressing Oxidative Stress and Inflammation in Denervated Mice
Simiao Wan attenuates high-fat diet-induced hyperlipidemia in mice by modulating the gut microbiota–bile acid axis
Correction to: Hypoxic-Ischemic Encephalopathy: Pathogenesis and Promising Therapies
Mitochondrial dysfunction: roles in skeletal muscle atrophy
Oxidative stress: Roles in skeletal muscle atrophy
Ligand recognition and G-protein coupling of trace amine receptor TAAR1
WWP2 binds to NKRF, enhances the NF-κB signaling, and promotes malignant phenotypes of acute myeloid leukemia cells
Inflammation: Roles in Skeletal Muscle Atrophy
A Novel Drug Combination of Mangiferin and Cinnamic Acid Alleviates Rheumatoid Arthritis by Inhibiting TLR4/NFκB/NLRP3 Activation-Induced Pyroptosis
Potential Therapeutic Strategies for Skeletal Muscle Atrophy
Biogenesis and function of extracellular vesicles in pathophysiological processes of skeletal muscle atrophy
Diabetic Muscular Atrophy: Molecular Mechanisms and Promising Therapies
Safflor Yellow B Attenuates Ischemic Brain Injury via Downregulation of Long Noncoding AK046177 and Inhibition of MicroRNA-134 Expression in Rats
Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation
miR-199a modulates cisplatin resistance in ovarian cancer by targeting Hif1α